Novartis/BeiGene Opt For PD-1/TIGIT Combo For NSCLC In US
Defocus On 2L Monotherapy
The two companies have ceased to seek US approval for tislelizumab as a monotherapy for second-line non-small cell lung cancer and are instead seeming to pin their hopes on a combination with BeiGene’s anti-TIGIT antibody ociperlimab in the first-line setting.
